Related Experiment Videos
Anti-sense oligonucleotides as potential antitumour agents: prospective views and preliminary results
1Institut Gustave Roussy, UA 147 CNRS, U 140 INSERM, Villejuiff, France.
Abstract:
The expression of some proto-oncogenes (c-myc, N-myc, epidermal growth factor receptor) is frequently enhanced in several human malignant tissues. The reduction of level of this expression through the use of anti-sense RNA or anti-sense oligodeoxynucleotides might therefore offer a new way to modify at the somatic level some genetic traits controlled by these oncogenes and possibly related to the maintenance of the transformed phenotype. This approach, although interesting, is paved with considerable conceptual and technical difficulties: multigene involvement in many natural oncogenic processes as well as delivery and stability of the anti-sense nucleic acids. This paper briefly discusses some of these points and presents preliminary results obtained with the alpha-anomeric oligodeoxyribonucleotides.
Insights
Targeting proto-oncogenes like c-myc with anti-sense nucleic acids offers a novel cancer therapy approach. This study explores the potential and challenges of using alpha-anomeric oligodeoxyribonucleotides to reduce oncogene expression.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Proto-oncogene expression, including c-myc, N-myc, and epidermal growth factor receptor, is often elevated in human cancers.
- These oncogenes play a crucial role in maintaining the transformed phenotype of malignant cells.
Purpose of the Study:
- To investigate the potential of anti-sense nucleic acids to reduce proto-oncogene expression.
- To explore the feasibility of using alpha-anomeric oligodeoxyribonucleotides as a therapeutic strategy for cancer.
Main Methods:
- Utilizing anti-sense RNA and anti-sense oligodeoxynucleotides to target specific proto-oncogenes.
- Employing alpha-anomeric oligodeoxyribonucleotides in preliminary experiments.
Main Results:
- Preliminary results with alpha-anomeric oligodeoxyribonucleotides are presented.
- The study acknowledges significant conceptual and technical challenges in this approach.
Conclusions:
- Anti-sense nucleic acid therapy holds promise for modifying oncogene expression at the somatic level.
- Further research is needed to overcome challenges related to multigene involvement, delivery, and stability of anti-sense agents.